Lung Cancer

Luis E. Raez, MD, discusses major trials in squamous NSCLC and what lies ahead for immunotherapy.

Konstantinos Leventakos, MD, discusses updates in personalized medicine for patients with stage III lung cancer.

Joseph Leach, MD, medical oncologist at Minnesota Oncology, discusses the use of brigatinib (Alunbrig) in ALK-positive non–small cell lung cancer (NSCLC).

Arek Z. Dudek, MD, PhD, discusses the research surrounding osimertinib in the treatment of patients with EGFR-positive non–small cell lung cancer.

Naomi Fujioka, MD, discusses the clinical implications of the PACIFIC trial in NSCLC treatment and additional questions that are informing planned and ongoing trial designs in stage III disease.

Joseph Leach, MD, a medical oncologist at Minnesota Oncology, discussed the emergence of ALK inhibitors in lung cancer and the importance of testing for such molecular abnormalities.

Inga T. Lennes, MD, MBA, MPH, senior vice president of Performance Improvement and Service Excellence of the Mass General Physicians Organization, medical director, Ambulatory Services, and director of clinical quality, Massachusetts General Hospital Cancer Center, discusses ongoing research on screening techniques for lung cancer.

Liposomal irinotecan achieved disease control in almost half of patients as a second-line treatment for small cell lung cancer, according to findings from Part 1 of the phase II/III RESILIENT trial presented at the 2019 World Conference on Lung Cancer.

The investigational Trop-2–targeting antibody-drug conjugate DS-1062 demonstrated antitumor activity in unselected patients with unresectable, advanced non–small cell lung cancer.

Single-agent atezolizumab extended overall survival compared with chemotherapy as a frontline treatment for patients with advanced nonsquamous and squamous non–small cell lung cancer and high PD-L1 expression, according to topline findings from the phase III IMpower110 trial.

The FDA has granted a breakthrough therapy designation to the MET inhibitor tepotinib as a treatment for certain patients with metastatic non–small cell lung cancer with MET exon14-skipping alterations.

Rosario Garcia Campelo, MD, medical oncologist, University Hospital Caruna, talks about a randomized trial assessing health-related quality of life in patients with ALK-positive non–small cell lung cancer patients who were treated with brigatinib versus crizotinib.

Ramaswamy Govindan, MD, professor of medicine, Washington University School of Medicine discusses the results of a phase I study looking at safety, tolerability, pharmacokinetics, and efficacy of KRAS G12C inhibitor, AMG 510 in patients with non-small cell lung cancer.

Targeted therapies for non­–small cell lung cancer produced mixed results in a novel multiarm clinical trial that matched tumor mutations to drugs targeting the mutations.

The addition of atezolizumab (Tecentriq) to carboplatin and nab-paclitaxel (Abraxane) showed a clinical overall survival benefit among a subgroup of patients with advanced squamous non–small cell lung cancer.

Alexander Drilon, MD, research director, Memorial Sloan Kettering Cancer Center, discusses the results of LIBRETTO-001, a phase I/II trial of RET inhibitor, selpercatinib in patients with RET fusion non-small cell lung cancers.

Anna F. Farago, MD, PhD, assistant professor of medicine, Harvard Medical School, discusses the updated activity of larotrectinib in NTRK fusion–positive lung cancer.

Almost 70% of patients with previously treated RET-fusion–positive non–small cell lung cancer had objective responses to the RET inhibitor selpercatinib (LOXO-292), according to data from the phase I/II LIBRETTO-001 trial presented at the 2019 World Conference on Lung Cancer.

The FDA has granted a fast track designation to AMG 510 for the treatment of patients with KRAS G12C–mutated metastatic non–small cell lung cancer who received prior therapy.

Patients with untreated extensive-stage small cell lung cancer had statistically significant improvement in overall survival when the PD-L1 inhibitor durvalumab (Imfinzi) was added to chemotherapy.

The first-in-class AXL inhibitor bemcentinib (BGB324) demonstrated activity in combination with the PD-1 inhibitor pembrolizumab in patients with advanced non–small cell lung cancer who had no prior exposure to immunotherapy.

Pasi A. Jänne, MD, PhD, discusses 3 studies of novel agents for targeting EGFR-mutant and HER2-positive lung cancers and the next steps in getting the research to cancer clinics.

The investigational KRAS inhibitor AMG 510 induced near-universal disease control in patients with advanced non–small cell lung cancer with KRAS mutations.

The European Commission has approved atezolizumab for use in combination with carboplatin and nab-paclitaxel for the first-line treatment of adult patients with advanced, nonsquamous non–small cell lung cancer.

The FDA has granted a breakthrough therapy designation to capmatinib (INC280) as a first-line treatment for patients with MET exon14 skipping—mutated non–small cell lung cancer.